Abdul Alawwa, MD
Cardiovascular Disease · Lapeer, MINPI 1013904093
Payments from drug & device makers
Across 761 payments — averaging $283.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$114K
- Boston Scientific$40K
- Medtronic$17K
- Johnson & Johnson$15K
- Biotronik Inc.$11K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
- plus $10K from 21 others
What the payments were for
- Consulting fees$91,53357%
- Speaking & faculty fees$32,63620%
- Travel & lodging$19,45812%
- Food & beverage$16,68110%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 452 | $114,283 |
| Boston Scientific | 57 | $40,480 |
| Medtronic(2 entities) | 90 | $16,678 |
| Johnson & Johnson | 40 | $14,630 |
| Biotronik Inc. | 26 | $11,413 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $7,914 |
| Sanofi-aventis U.S. LLC | 13 | $3,885 |
| Novartis | 8 | $2,996 |
| Pfizer | 14 | $2,326 |
| Inari Medical, Inc. | 1 | $156 |
| Astellas Pharma US Inc | 4 | $142 |
| Cardiva Medical, Inc. | 2 | $141 |
| Amgen | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 7 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $80 |
| Actelion Pharmaceuticals US, Inc. | 4 | $50 |
| Cordis US CORP. | 2 | $42 |
| Smith+Nephew | 1 | $25 |
| Cleerly, Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Sanofi | 1 | $21 |
| Edwards Lifesciences | 1 | $18 |
| Medicomp Inc | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Preventice Services, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accent Pacemaker$21,916
- Allure CRT Pacemaker$18,082
- XARELTO$14,057
- Ensite Cardiac Mapping System$10,381
- EnSite Precision Cardiac Mapping System$8,060
- LifeVest$7,500
- ALLURE$7,481
- Mitra Clip system$4,675
- GALLANT$4,631
- DISEASE STATE$3,766
- Farapulse$3,543
- Acculink carotid stent system$3,375
- Advisor Catheter$3,150
- ENTRESTO$2,705
- ELIQUIS$2,100
- Arctic Front$1,790
- Allure Quadra RF CRT Pacemaker$1,780
- Acticor 7 VR-T DX$973
- Solia$944
- EVERA MRI XT DR SURESCAN$915
How this compares
$215,609 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 856 | $1,077,663 |
| XareltoRivaroxaban | 310 | $425,697 |
| EntrestoSacubitril/Valsartan | 221 | $323,579 |
| MultaqDronedarone Hcl | 128 | $220,708 |
| Repatha SureclickEvolocumab | 84 | $101,963 |
| FarxigaDapagliflozin Propanediol | 51 | $61,909 |
| JardianceEmpagliflozin | 21 | $29,445 |
| Praluent PenAlirocumab | 13 | $17,479 |
| Amiodarone Hcl | 434 | $13,515 |
| Metoprolol Succinate | 667 | $13,013 |
| SotalolSotalol Hcl | 446 | $11,631 |
| Propafenone Hcl ErPropafenone Hcl | 58 | $11,606 |
| BrilintaTicagrelor | 13 | $10,659 |
| Atorvastatin Calcium | 580 | $9,795 |
| Ranolazine ErRanolazine | 48 | $9,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,326 | $1,077,663856 claims |
| Johnson & JohnsonXarelto | $14,630 | $425,697310 claims |
| NovartisEntresto | $2,996 | $323,579221 claims |
| Sanofi-aventis U.S. LLCMultaq | $3,885 | $220,708128 claims |
| AstraZenecaFarxiga, Brilinta | $13 | $72,56764 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Lapeer
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.